$40.87
Live
Insights on Qiagen Nv
Revenue is up for the last 2 quarters, 475.89M → 509.16M (in $), with an average increase of 6.5% per quarter
Netprofit is up for the last 2 quarters, 77.81M → 97.66M (in $), with an average increase of 20.3% per quarter
In the last 1 year, Iqvia Holdings Inc. has given 25.6% return, outperforming this stock by 34.4%
In the last 3 years, Thermo Fisher Scientific, Inc. has given 3.7% return, outperforming this stock by 25.4%
0.72%
Downside
Day's Volatility :1.11%
Upside
0.39%
14.93%
Downside
52 Weeks Volatility :27.18%
Upside
14.41%
Period | Qiagen Nv | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -8.66% | 1.7% | 0.0% |
6 Months | 9.2% | 11.3% | 0.0% |
1 Year | -8.79% | 5.4% | 1.3% |
3 Years | -21.38% | 13.9% | -22.1% |
Market Capitalization | 9.3B |
Book Value | $17.2 |
Dividend Share | 0.0 |
Dividend Yield | 2.94% |
Earnings Per Share (EPS) | 1.52 |
PE Ratio | 27.56 |
PEG Ratio | 1.25 |
Wall Street Target Price | 50.97 |
Profit Margin | 17.37% |
Operating Margin TTM | 23.86% |
Return On Assets TTM | 4.49% |
Return On Equity TTM | 9.38% |
Revenue TTM | 2.0B |
Revenue Per Share TTM | 8.88 |
Quarterly Revenue Growth YOY | 2.1999999999999997% |
Gross Profit TTM | 1.4B |
EBITDA | 638.9M |
Diluted Eps TTM | 1.52 |
Quarterly Earnings Growth YOY | 0.09 |
EPS Estimate Current Year | 2.11 |
EPS Estimate Next Year | 2.31 |
EPS Estimate Current Quarter | 0.55 |
EPS Estimate Next Quarter | 0.51 |
What analysts predicted
Upside of 24.71%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 1.5B | ↑ 5.95% |
Net Income | 190.4M | ↑ 371.31% |
Net Profit Margin | 12.68% | ↑ 9.83% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 1.5B | ↑ 1.64% |
Net Income | -41.5M | ↓ 121.77% |
Net Profit Margin | -2.72% | ↓ 15.4% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 1.9B | ↑ 22.53% |
Net Income | 73.6M | ↓ 277.64% |
Net Profit Margin | 3.94% | ↑ 6.66% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 2.3B | ↑ 20.39% |
Net Income | 512.6M | ↑ 596.09% |
Net Profit Margin | 22.77% | ↑ 18.83% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 2.1B | ↓ 4.89% |
Net Income | 423.2M | ↓ 17.44% |
Net Profit Margin | 19.76% | ↓ 3.01% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 2.0B | ↓ 8.23% |
Net Income | 341.3M | ↓ 19.35% |
Net Profit Margin | 17.37% | ↓ 2.39% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 499.6M | ↓ 3.08% |
Net Income | 82.4M | ↓ 14.76% |
Net Profit Margin | 16.49% | ↓ 2.26% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 498.0M | ↓ 0.33% |
Net Income | 88.8M | ↑ 7.83% |
Net Profit Margin | 17.84% | ↑ 1.35% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 485.4M | ↓ 2.53% |
Net Income | 85.0M | ↓ 4.29% |
Net Profit Margin | 17.52% | ↓ 0.32% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 494.9M | ↑ 1.95% |
Net Income | 80.8M | ↓ 5.0% |
Net Profit Margin | 16.33% | ↓ 1.19% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 475.9M | ↓ 3.83% |
Net Income | 77.8M | ↓ 3.67% |
Net Profit Margin | 16.35% | ↑ 0.02% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 509.2M | ↑ 6.99% |
Net Income | 97.7M | ↑ 25.5% |
Net Profit Margin | 19.18% | ↑ 2.83% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 5.7B | ↑ 14.09% |
Total Liabilities | 3.1B | ↑ 24.66% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 5.2B | ↓ 8.92% |
Total Liabilities | 2.7B | ↓ 13.31% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 6.0B | ↑ 14.05% |
Total Liabilities | 3.5B | ↑ 29.24% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 6.1B | ↑ 2.94% |
Total Liabilities | 3.1B | ↓ 12.55% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 6.3B | ↑ 2.29% |
Total Liabilities | 2.8B | ↓ 7.52% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 6.1B | ↓ 2.74% |
Total Liabilities | 2.3B | ↓ 18.21% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 6.5B | ↑ 5.9% |
Total Liabilities | 3.2B | ↑ 11.06% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 6.3B | ↓ 3.51% |
Total Liabilities | 2.8B | ↓ 11.53% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 6.3B | ↓ 0.14% |
Total Liabilities | 2.7B | ↓ 3.66% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 6.3B | ↑ 1.09% |
Total Liabilities | 2.7B | ↑ 0.22% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 5.9B | ↓ 6.94% |
Total Liabilities | 2.2B | ↓ 18.75% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 6.1B | ↑ 3.53% |
Total Liabilities | 2.3B | ↑ 4.27% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 359.5M | ↑ 25.36% |
Investing Cash Flow | -211.4M | ↓ 54.48% |
Financing Cash Flow | 360.4M | ↓ 6.92% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 330.8M | ↓ 7.97% |
Investing Cash Flow | -222.3M | ↑ 5.17% |
Financing Cash Flow | -639.1M | ↓ 277.32% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 492.3M | ↑ 48.79% |
Investing Cash Flow | -443.3M | ↑ 99.43% |
Financing Cash Flow | -74.3M | ↓ 88.37% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 639.0M | ↑ 29.81% |
Investing Cash Flow | -202.4M | ↓ 54.33% |
Financing Cash Flow | -150.4M | ↑ 102.32% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 715.3M | ↑ 11.93% |
Investing Cash Flow | -735.6M | ↑ 263.38% |
Financing Cash Flow | -125.8M | ↓ 16.34% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 211.6M | ↑ 23.05% |
Investing Cash Flow | -44.4M | ↓ 82.33% |
Financing Cash Flow | 408.0M | ↑ 1658.18% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 124.3M | ↓ 41.24% |
Investing Cash Flow | -133.3M | ↑ 200.01% |
Financing Cash Flow | -546.4M | ↓ 233.91% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 71.9M | ↓ 42.14% |
Investing Cash Flow | 156.3M | ↓ 217.2% |
Financing Cash Flow | -9.8M | ↓ 98.2% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 111.5M | ↑ 54.99% |
Investing Cash Flow | 156.3M | ↑ 0.0% |
Financing Cash Flow | -15.5M | ↑ 57.43% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 124.7M | ↑ 11.85% |
Investing Cash Flow | 248.4M | ↑ 58.93% |
Financing Cash Flow | -401.1M | ↑ 2492.37% |
Sell
Neutral
Buy
Qiagen Nv is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Qiagen Nv | -3.04% | 9.2% | -8.79% | -21.38% | 4.09% |
Idexx Laboratories, Inc. | -6.69% | 19.77% | 2.28% | -11.49% | 117.09% |
Agilent Technologies Inc. | -5.54% | 32.97% | 5.46% | 0.11% | 79.21% |
Thermo Fisher Scientific, Inc. | 0.67% | 33.29% | 5.29% | 16.87% | 114.21% |
Danaher Corp. | 1.05% | 29.98% | 7.94% | -2.98% | 92.05% |
Iqvia Holdings Inc. | -3.23% | 32.9% | 25.63% | 3.18% | 75.33% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Qiagen Nv | 27.56 | 27.56 | 1.25 | 2.11 | 0.09 | 0.04 | 0.03 | 17.2 |
Idexx Laboratories, Inc. | 49.04 | 49.04 | 4.75 | 11.13 | 0.81 | 0.23 | NA | 17.88 |
Agilent Technologies Inc. | 33.3 | 33.3 | 2.7 | 5.5 | 0.21 | 0.08 | 0.01 | 21.12 |
Thermo Fisher Scientific, Inc. | 37.17 | 37.17 | 2.81 | 21.53 | 0.13 | 0.05 | 0.0 | 120.87 |
Danaher Corp. | 46.53 | 46.53 | 3.13 | 7.15 | 0.08 | 0.04 | 0.0 | 72.16 |
Iqvia Holdings Inc. | 32.69 | 32.69 | 1.33 | 11.11 | 0.23 | 0.05 | NA | 33.67 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Qiagen Nv | Buy | $9.3B | 4.09% | 27.56 | 17.37% |
Idexx Laboratories, Inc. | Buy | $41.0B | 117.09% | 49.04 | 23.08% |
Agilent Technologies Inc. | Buy | $40.8B | 79.21% | 33.3 | 18.35% |
Thermo Fisher Scientific, Inc. | Buy | $219.3B | 114.21% | 37.17 | 13.99% |
Danaher Corp. | Buy | $187.5B | 92.05% | 46.53 | 18.55% |
Iqvia Holdings Inc. | Buy | $43.4B | 75.33% | 32.69 | 9.06% |
Massachusetts Financial Services Company
Vanguard Group Inc
BlackRock Inc
Wellington Management Company LLP
Amundi
Fidelity International Ltd
In the quarter ending March,2024. Qiagen Nv has declared dividend of $1.28
Read Moreqiagen is the leading global provider of sample to insight solutions to transform biological materials into valuable molecular insights. qiagen sample technologies isolate and process dna, rna and proteins from blood, tissue and other materials. assay technologies make these biomolecules visible and ready for analysis. bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. automation solutions tie these together in seamless and cost-effective molecular testing workflows. qiagen provides these workflows to more than 500,000 customers around the world in molecular diagnostics (human healthcare), applied testing (forensics, veterinary testing and food safety), pharma (pharmaceutical and biotechnology companies) and academia (life sciences research). as of june 30, 2015, qiagen employed approximately 4,400 people in over 35 locations worldwide. further information can be found at http://www.qiagen.com.
Organization | Qiagen Nv |
Employees | 5191 |
CEO | Mr. Thierry Bernard |
Industry | Health Technology |